About Us

Our Mission

Bring consistency, high-quality and standardization to make medical cannabis accessible for those who need it. 

Panaxia is modernizing the medical field with revolutionary pharmaceutical solutions that utilize the unique properties and benefits of medical cannabis. As a leader in this rapidly developing medical arena, Panaxia is spearheading the adoption of cannabis-based treatments through a variety of familiar delivery methods that can radically improve the lives of those with a wide range of medical conditions.

Our Story

Decades of experience to lead the way forward.

 Leveraging over four decades of experience in the pharmaceutical industry, Panaxia is part of a leading group of Israeli pharmaceutical companies. Thanks to our relentless emphasis on research and development, today our entire group of companies offers more than 600 medical products in over 30 international markets to treat a wide range of symptoms and conditions.

Our Quest

Research. Develop. Repeat.

 As pharmaceutical research on cannabis continues to evolve, we intend to stay at the forefront of the field. With over 20 percent of our workforce dedicated to research and development, we are committed to continuously increasing our knowledge and understanding of this plant’s wide range of therapeutic benefits. Our goal is to increase accessibility to pharmaceutical cannabis with cutting-edge products and a variety of new and familiar delivery methods.

Our Commitment

Quality and accuracy caregivers and patients can depend on.

 As with any other pharmaceutical product, standardization, consistency, and accuracy of dosage are essential. Until now, the absence of these fundamental attributes has limited cannabis’ therapeutic potential. Panaxia is committed to changing all that. By using the most advanced analytical and validation methods, we are developing dosage forms that deliver the same amount of active ingredients to patients time after time.

Our Team.
Led by Experience.

Executive Team

4-298x300_0007_1-ns8ht3fwntp6mv5bjtw5il8p7avuoo6vdah0ors1pi

Dadi Segal, PhD, MBA, B.Ph 
Chief Executive Officer

4-298x300_0006_555-e1520439064605-nn28a0dlx4jtkkscnqx2ct3l8g8yjek0qr3ym0lx9c

Assi Rotbart, LL.b, B.Sc 
Executive Board Member

Eran Goldberg, PhD
Chief Technology Officer

Gil Benyamini, MBA, B.Sc 
Chief Financial Officer

Prof. Aaron Ciechanover
Advisory Board Member

Prof. David (Dedi) Meiri 
Advisory Board Member

Dr. Noa Leibovitch 
Advisory Board Member

Close Menu